ClinicalTrials.Veeva

Menu

Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

D

Dong-A ST

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: Mirabegron 50mg
Drug: DA-8010 5mg
Drug: Paroxetine 20mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT05992428
DA8010_DIPM_I

Details and patient eligibility

About

This is an open-label, 2-Part, phase 1 study to evaluate drug interactions when DA-8010 is co-administered with Paroxetine or Mirabegron in healthy adult subjects

Enrollment

37 patients

Sex

All

Ages

19 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy adult volunteer 19 years to 50 years
  • Body weight in the range of 40.0 to 90.0 kg and body mass index in the range of 18 to 28kg/m2
  • The subjects personally signed and dated informed consent document after informed of all patient aspects of the study, fully understanding and determined spontaneously to participate
  • In the case of female volunteers, those who are not necessarily pregnant or lactating or who are in a surgical infertility condition (both tubular obstruction, hysterectomy, bilateral tubular resection, etc.)
  • The subjects who are judged appropriate to participate this clinical trial according to the physical examination, routine laboratory examination and questionnaire

Exclusion criteria

  • Subject with serious active hepatobiliary (severe hepatic failure, etc.), renal(severe renal impairment, etc.), neurologic, immunologic, respiratory, digestive, endocrine, hematologic, cardiovascular(heart failure, Torsades de pointes, etc), urologic, psychological disease or history of such disease
  • Subject with gastrointestinal disease (peptic ulcer, gastritis, gastrospasm, gastroesophageal reflux disease, Crohn's disease, etc.) or history of such disease/surgery (excluding simple appendic surgery, hernia surgery, hemorrhoid surgery)
  • Subject Hypersensitive to any of the IP components or other drug components(Aspirin, Antibiotics, etc.)
  • Subject who is positive for serum test results (hepatitis B test, hepatitis C test, HIV test, syphilis test)
  • Subject who have history of drug/alcohol abuse or Positive in Urine drug screen test
  • Subject who determined that Investigator is unfit to participate in a clinical trial due to other reasons other than the above items

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

37 participants in 1 patient group

Part 1 or 2
Experimental group
Description:
\[Part 1\] DA-8010 5mg + Paroxetine 20mg \[Part 2\] DA-8010 5mg + Mirabegron 50mg
Treatment:
Drug: Mirabegron 50mg
Drug: DA-8010 5mg
Drug: Paroxetine 20mg

Trial contacts and locations

1

Loading...

Central trial contact

Seung Hwan Lee, PhD; Hyunwook Ryu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems